Phase II Pilot Evaluation of Infusional 8 Cl-cAMP in the Treatment of Relapsed or Refractory Multiple Myeloma
OBJECTIVES: I. Determine the safety of 8-chloro-cyclic adenosine monophosphate
(8-chloro-cAMP) in patients with recurrent or refractory multiple myeloma. II. Evaluate the
efficacy of this regimen in these patients. III. Determine the pharmacokinetics of this
regimen in these patients.
OUTLINE: Patients receive 8-chloro-cyclic adenosine monophosphate (8-chloro-cAMP) over 120
hours every 2 weeks for up to 4 courses. Beginning with course 5, patients with stable or
responsive disease receive 8-chloro-cAMP over 120 hours every 3 weeks until disease
progression. Patients are followed every 3 months until death.
PROJECTED ACCRUAL: A maximum of 29 patients will be accrued for this study within 12-18
Primary Purpose: Treatment
Ann Traynor, MD
Robert H. Lurie Cancer Center
United States: Federal Government
|Robert H. Lurie Comprehensive Cancer Center, Northwestern University||Chicago, Illinois 60611|